Pharmaceutical company Merz Aesthetics has received US Food and Drug Administration (FDA) approval for Ultherapy PRIME for skin laxity on the knees.
The company shares that this approval on the significant expansion of Ultherapy PRIME’s growing portfolio of cleared body indication. According to Merz Aesthetics, Ultherapy PRIME treats multiple skin depths, allowing practitioners to tailor treatment to each patient’s unique anatomy. By stimulating the body’s natural collagen and elastin production, it delivers a non-surgical lift with natural-looking results for the face and body. The company further notes that it is designed with patient convenience in mind, it typically requires a single session with no downtime and is safe for all skin tones.
Dr Samantha Kerr, chief scientific officer at Merz Aesthetics, commented, “The new knees indication marks another monumental moment for Ultherapy PRIME. It underscores our commitment to advancing science-backed innovation and expanding non-invasive treatment possibilities for healthcare professionals and their patients.”